KPKaustubha D. Patil

Kaustubha D. Patil

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kaustubha D. Patil has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An Ex Vivo Evaluation of Air Intrusion Into Pulsed Field Ablation Sheaths During Ablation and Mapping Catheter Insertion

    by Chad Gier, Erik Simon, Aamir Ahmed, Graham Peigh, Shivam Patel, Jayson Baman, Aravind Kalluri, Kasen Culler, Kaustubha D. Patil, Anna Pfenniger, et al.

    Introduction: Pulsed field ablation (PFA) is the newest ablation technology, and currently, no data exist on the amount of air intrusion into new, large bore PFA sheaths during ablation or mapping catheter insertion. Methods: An ex vivo study was performed using various combinations of commercially available PFA ablation catheters and sheaths. Common mapping catheters and a non‐PFA steerable sheath were also evaluated as a reference. The siphon principle was used to create negative pressure to simulate left atrial pressure during spontaneous inspiration. Ablation and mapping catheters were advanced to the end of the sheaths under negative pressure and then removed. Air was withdrawn from the sheaths and was measured in milliliters (mL). Results: A total of 55 trials were performed. The average volume of air intrusion with all sheath/catheter combinations was 9.6 + 5.2 mL. The 13 Fr (inner diameter) Faradrive sheath (Boston Scientific Inc.) entrained significantly more air (16.5 + 4.1 mL) compared with the 12 Fr FlexCath Contour sheath (Medtronic Inc.) (6.1 + 2.7 mL, p < 0.01), 13 Fr Agilis NxT sheath (Abbott Inc.) (8.7 + 1.8 mL, p < 0.01), and Vizigo sheath (Johnson & Johnson MedTech Inc.) (5.8 + 2.1 mL, p < 0.01), regardless of the catheter used. There was significantly higher volume of air intrusion with the Farawave ablation catheter through the Faradrive sheath (13.6 + 2.0 mL) than through the 13 Fr Agilis (9.4 + 2.1 mL, p = 0.03) or the PulseSelect through FlexCath Contour sheath (4.0 + 2.7 mL, p < 0.01). Mapping catheters entrained significantly more air than ablation catheters in both the Faradrive (18.0 ± 4.1 mL vs. 13.6 ± 4.1 mL, p = 0.04) and the FlexCath Contour (7.1 ± 2.2 mL vs. 4.0 ± 2.7 mL, p = 0.03). Conclusion: Using a model that simulates left atrial PFA in spontaneously breathing patients, a large volume of air intrusion was observed during insertion and removal of ablation and mapping catheters into new, large bore PFA sheaths. New sheath designs are needed to minimize air intrusion during catheter exchanges to avoid air embolism when performing PFA using left atrial delivery sheaths.


  • Open Access

    Rates of and Indications for Subcutaneous ICD Extraction: A Multihospital Healthcare System Analysis

    by Arati Gangadharan, Graham Peigh, Mariam Arif, Jayson Baman, Kaustubha Patil, Alexandru Chicos, Susan S. Kim, Albert C. Lin, Anna Pfenniger, Rod S. Passman, et al.

    Introduction: The subcutaneous implantable cardioverter defibrillator (S‐ICD) is an alternative to a transvenous ICD in patients who meet the criteria for ICD implantation without concurrent need for cardiac pacing. The objective of this study is to examine the rates of and indications for S‐ICD removal and extraction.Methods: A retrospective analysis of all patients who underwent S‐ICD implantation between 2010 and 2022 at a single multihospital healthcare system was performed. The primary endpoint was S‐ICD removal or extraction. Patient and device characteristics were abstracted from the electronic medical record. Univariate and multivariate analyses were completed to determine factors associated with S‐ICD extraction.Results: A total of 372 patients (69.5% male; 48.6 ± 14.4 years old) underwent S‐ICD implantation during the study period. There were 22 (5.9%) patients (81.8% male; 52.1 ± 13.2 years old) who underwent S‐ICD extraction over a median follow‐up period of 4.4 [2.0−6.5] years. The median length of time between implantation and extraction was 39.6 [8.3−64.6] months. The most common indications for S‐ICD extraction were the need for bradycardia pacing (frequency among extractions, 18.2%), infection (22.7%), and inappropriate shocks due to oversensing (22.7%). A smoking history and higher body mass index were independently associated with S‐ICD extraction.Conclusions: The overall rate of S‐ICD extraction over 4.4 [2.0−6.5] years was 5.9%, with the most common indications for extraction being the need for bradycardia pacing, infection, and inappropriate shocks due to oversensing. A smoking history and high body mass index are associated with increased rates of S‐ICD extraction. With appropriate patient selection for the S‐ICD, the need to remove the device after implantation is low.


  • Open Access

    Rates of and Indications for Subcutaneous ICD Extraction: A Multihospital Healthcare System Analysis

    by Arati Gangadharan, Graham Peigh, Mariam Arif, Jayson R. Baman, Kaustubha Patil, Alexandru Chicos, Susan S. Kim, Albert Lin, Anna Pfenniger, Rod Passman, et al.

    Introduction : The subcutaneous implantable cardioverter defibrillator (S-ICD) is an alternative to a transvenous ICD in patients who meet criteria for ICD implantation without concurrent need for cardiac pacing. The objective of this study is to examine the rates of and indications for S-ICD removal and extraction. Methods : A retrospective analysis of all patients who underwent S-ICD implantation between 2010 and 2022 at a single multihospital healthcare system was performed. The primary endpoint was S-ICD removal or extraction. Patient and device characteristics were abstracted from the electronic medical record. Univariate and multivariate analyses were completed to determine factors associated with S-ICD extraction. Results : A total of 372 patients (69.5% male; 48.6 ± 14.4 years old) underwent S-ICD implantation during the study period. There were 22 (5.9%) patients (81.8% male; 52.1 ± 13.2 years old) who underwent S-ICD extraction over a median follow up period of 4.4 [2.0-6.5] years. The median length of time between implantation and extraction was 39.6 [8.3-64.6] months. The most common indications for S-ICD extraction were need for bradycardia pacing (incidence, 1.08%), infection (1.34%), and inappropriate shocks due to oversensing (1.34%). A smoking history and higher body mass index were independently associated with S-ICD extraction. Conclusions : The overall rate of S-ICD extraction over 4.4 [2.0-6.5] years was 5.9%, with the most common indications for extraction being need for bradycardia pacing, infection, and inappropriate shocks due to oversensing. A smoking history and high body mass index are associated with increased rates of S-ICD extraction. With appropriate patient selection for the S-ICD, the need to remove the device after implantation is low.

  • Open Access

    Association between high‐density mapping of atypical atrial flutter, clinical outcomes and healthcare utilization

    by Joshua Sink, Kasen Culler, Lakshmi Uppalapati, Nicola Lancki, Graham Peigh, Graham Lohrmann, Mahmoud Elsayed, Herman Carneiro, Jayson Baman, Anna Pfenniger, et al.

    Background: Success of atypical atrial flutter (AAFL) ablation has historically been limited by difficulty mapping the complex re‐entrant circuits involved. While high‐density (HD) mapping has become commonplace in clinical practice, there are limited data on outcomes of HD versus non‐HD mapping for AAFL ablation.Objective: To compare clinical outcomes and healthcare utilization using HD mapping versus non‐HD mapping for AAFL ablation.Methods: Retrospective analysis of all AAFL procedures between 2005 and 2022 at an academic medical center was conducted. Procedures utilizing a 16‐electrode HD Grid catheter and Precision mapping system were compared to procedures using prior generation 10–20 electrode spiral catheters and the Velocity system (Abbott, IL). Cox regression models and Poisson regression models were utilized to examine procedural and healthcare utilization outcomes. Models were adjusted for left ventricular ejection fraction, CHA2DS2‐VASc, and history of prior ablation.Results: There were 108 patients (62% HD mapping) included in the analysis. Baseline clinical characteristics were similar between groups. Use of HD mapping was associated with a higher rate of AAFL circuit delineation (92.5% vs. 76%; p = .014) and a greater adjusted procedure success rate, defined as non‐inducibility at procedure end, (aRR (95% CI) 1.26 (1.02–1.55) p = .035) than non‐HD mapping. HD mapping was also associated with a lower rate of ED visits (aIRR (95% CI) 0.32 (0.14–0.71); p = .007) and hospitalizations (aIRR (95% CI) 0.32 (0.14–0.68); p = .004) for AF/AFL/HF through 1 year. While there was a lower rate of recurrent AFL through 1 year among HD mapping cases (aHR (95% CI) 0.60 (0.31–1.16) p = .13), statistical significance was not met likely due to the low sample size and higher rate of ambulatory rhythm monitoring in the HD group (61% vs. 39%, p = .025).Conclusion: Compared to non‐HD mapping, AAFL ablation with HD mapping is associated with improvements in the ability to define the AAFL circuit, greater procedural success, and a reduction in the number of ED visits and hospitalization for AF/AFL/HF.


  • Open Access

    Implementation of an intravenous sotalol initiation protocol: Implications for feasibility, safety, and length of stay

    by Jessica Charron, Dana Fugaro, Scott Spoolstra, Rachel Kaplan, Graham Lohrmann, Xu Gao, Hawkins Gay, Rod Passman, Susan Kim, Albert C. Lin, et al.

    Introduction: Oral sotalol initiation requires a multiple‐day, inpatient admission to monitor for QT prolongation during loading. A 1‐day intravenous (IV) sotalol loading protocol was approved by the United States Food and Drug Administration in March 2020, but limited data on clinical use and administration currently exists. This study describes implementation of an IV sotalol protocol within an integrated health system, provides initial efficacy and safety outcomes, and examines length of stay (LOS) compared with oral sotalol initiation.Methods: IV sotalol was administered according to a prespecified initiation protocol to adult patients with refractory atrial or ventricular arrhythmias. Baseline characteristics, safety and feasibility outcomes, and LOS were compared with patients receiving oral sotalol over a similar time period.Results: From January 2021 to June 2022, a total of 29 patients (average age 66.0 ± 8.6 years, 27.6% women) underwent IV sotalol load and 20 patients (average age 60.4 ± 13.9 years, 65.0% women) underwent oral sotalol load. The load was successfully completed in 22/29 (75.9%) patients receiving IV sotalol and 20/20 (100%) of patients receiving oral sotalol, although 7/20 of the oral sotalol patients (35.0%) required dose reduction. Adverse events interrupting IV sotalol infusion included bradycardia (seven patients, 24.1%) and QT prolongation (three patients, 10.3%). No patients receiving IV or oral sotalol developed sustained ventricular arrhythmias before discharge. LOS for patients completing IV load was 2.6 days shorter (mean 1.0 vs. 3.6, p < .001) compared with LOS with oral load.Conclusion: IV sotalol loading has a safety profile that is similar to oral sotalol. It significantly shortens hospital LOS, potentially leading to large cost savings.


  • Open Access

    Esophageal temperature management during cryoballoon ablation for atrial fibrillation

    by Joshua Sink, Kiran Nimmagadda, Manyun Zhao, Adin‐Cristian Andrei, Hawkins Gay, Rachel M. Kaplan, Xu Gao, Anna Pfenniger, Kaustubha D. Patil, Rishi Arora, et al.

    Introduction: Esophageal thermal injury (ETI) is a well‐recognized complication of atrial fibrillation (AF) ablation. Previous studies have demonstrated that direct esophageal cooling reduces ETI during radiofrequency AF ablation. The purpose of this study was to evaluate the use of an esophageal warming device to prevent ETI during cryoballoon ablation (CBA) for AF.Methods: This prospective, double‐blinded study enrolled 42 patients with symptomatic AF undergoing CBA. Patients were randomized to the treatment group with esophageal warming (42°C) using recirculated water through a multilumen, silicone tube inserted into the esophagus (EnsoETM®; Attune Medical) (WRM) or the control group with a luminal single‐electrode esophageal temperature monitoring probe (LET). Patients underwent upper endoscopy esophagogastroduodenoscopy (EGD) the following day. ETI was classified into four grades.Results: Baseline patient characteristics were similar between groups. Procedural characteristics including number of freezes, total freeze time, early freeze terminations, coldest balloon temperature, procedure duration, posterior wall ablation, and proton pump inhibitor and transesophageal echocardiogram use before procedure were not different between groups. The EGD was completed in 40/42 patients. There was significantly more ETI in the WRM group compared to the LET group (n = 8 [38%] vs. n = 1 [5%], p = 0.02). All ETI lesions were grade 1 (erythema) or 2 (superficial ulceration). Total freeze time in the left inferior pulmonary vein was predictive of ETI (360 vs. 300 s, p = 0.03).Conclusion: Use of a luminal heat exchange tube for esophageal warming during CBA for AF was paradoxically associated with a higher risk of ETI.


  • Open Access

    Implementation of an Intravenous Sotalol Initiation Protocol: Implications for Feasibility, Safety, and Length of Stay

    by Albert Liu, Jessica Charron, Dana Fugaro, Scott Spoolstra, Rachel Kaplan, Graham Lohrmann, Xu Gao, Hawkins Gay, Rod Passman, Susan S. Kim, et al.

    Introduction Oral sotalol initiation requires a multiple-day, inpatient admission to monitor for QT prolongation during loading. A one-day intravenous (IV) sotalol loading protocol was approved by the FDA in March 2020, but limited data on clinical use and administration currently exists. This study describes implementation of an IV sotalol protocol within an integrated health system, provides initial efficacy and safety outcomes, and examines length of stay compared to oral sotalol initiation. Methods IV sotalol was administered according to a pre-specified initiation protocol to adult patients with refractory atrial or ventricular arrhythmias. Baseline characteristics, safety and feasibility outcomes, and length of stay (LOS) were compared to patients receiving oral sotalol over a similar time period. Results From January 2021 to June 2022, a total of 29 patients (average age 66.0 ± 8.6 years, 27.6% women) underwent IV sotalol load and 20 patients (average age 60.4 ± 13.9 years, 65.0% women) underwent PO sotalol load. The load was successfully completed in 22/29 (75.9%) patients receiving IV sotalol and 20/20 (100%) of patients receiving oral sotalol, although 7/20 of the oral sotalol patients (35.0%) required dose reduction. Adverse events interrupting IV sotalol infusion included bradycardia (7 patients, 24.1%) and QT prolongation (3 patients, 10.3%). No patients receiving IV or oral sotalol developed sustained ventricular arrhythmias prior to discharge. LOS for patients completing IV load was 2.6 days shorter (mean 1.0 vs 3.6, p < 0.001) compared to LOS with oral load. Conclusion Intravenous sotalol loading has a safety profile that is similar to oral sotalol. It significantly shortens hospital LOS, potentially leading to large cost savings.

  • Open Access

    First-in-Human Use of a Novel 4D Intracardiac Echocardiography Catheter To Guide Interventional Electrophysiology Procedures

    by Rachel Kaplan, Akhil Narang, Hawkins Gay, Xu Gao, Mohammed Gibreal, Rishi Arora, Alexandru Chicos, Susan Kim, Rod Passman, Kaustubha Patil, et al.

    Introduction: Standard two-dimensional (2D), phased-array intracardiac echocardiography (ICE) is routinely used to guide interventional electrophysiology (EP) procedures. A novel four-dimensional (4D) ICE catheter (VeriSight Pro®, Philips, Andover, MA) can obtain 2D and three-dimensional (3D) volumetric images and cine-videos in real time (4D). The purpose of this study was to determine the early feasibility and safety of this 4D ICE catheter during EP procedures. Methods: The 4D ICE catheter was placed from the femoral vein in ten patients into various cardiac chambers to guide EP procedures requiring transseptal catheterization, including ablation for atrial fibrillation and left atrial appendage closure. 2D- and 3D- ICE images were acquired in real time by the electrophysiologist. A dedicated imaging expert performed digital steering to optimize and post-process 4D images. Results: Eight patients underwent pulmonary vein isolation (cryoballoon in 7 patients, pulsed field ablation in 1, additional radiofrequency left atrial ablation in 1). Two patients underwent left atrial appendage closure. High quality images of cardiac structures, transseptal catheterization equipment, guide sheaths, ablation tools, and closure devices were acquired with the ICE catheter tip positioned in the right atrium, left atrium, pulmonary vein, coronary sinus, right ventricle, and pulmonary artery. There were no complications. Conclusion: This is the first-in-human experience of a novel deflectable 4D ICE catheter used to guide EP procedures. 4D ICE imaging in safe and allows for acquisition of high-quality 2D and 3D images in real-time. Further use of 4D ICE will be needed to determine its added value for each EP procedure type.

  • Use of a novel 4D intracardiac echocardiography catheter to guide interventional electrophysiology procedures

    by Rachel M. Kaplan, Akhil Narang, Hawkins Gay, Xu Gao, Mohammed Gibreal, Rishi Arora, Alexandru Chicos, Susan Kim, Rod Passman, Kaustubha Patil, et al.

    Introduction: Standard two‐dimensional (2D), phased‐array intracardiac echocardiography (ICE) is routinely used to guide interventional electrophysiology (EP) procedures. A novel four‐dimensional (4D) ICE catheter (VeriSight Pro, Philips) can obtain 2D and three‐dimensional (3D) volumetric images and cine‐videos in real‐time (4D). The purpose of this study was to determine the early feasibility and safety of this 4D ICE catheter during EP procedures.Methods: The 4D ICE catheter was placed from the femoral vein in ten patients into various cardiac chambers to guide EP procedures requiring transseptal catheterization, including ablation for atrial fibrillation and left atrial appendage closure. 2D‐ and 3D‐ICE images were acquired in real‐time by the electrophysiologist. A dedicated imaging expert performed digital steering to optimize and postprocess 4D images.Results: Eight patients underwent pulmonary vein isolation (cryoballoon in seven patients, pulsed field ablation in one, additional radiofrequency left atrial ablation in one). Two patients underwent left atrial appendage closure. High quality images of cardiac structures, transseptal catheterization equipment, guide sheaths, ablation tools, and closure devices were acquired with the ICE catheter tip positioned in the right atrium, left atrium, pulmonary vein, coronary sinus, right ventricle, and pulmonary artery. There were no complications.Conclusion: This is the first experience of a novel deflectable 4D ICE catheter used to guide EP procedures. 4D ICE imaging is safe and allows for acquisition of high‐quality 2D and 3D images in real‐time. Further use of 4D ICE will be needed to determine its added value for each EP procedure type.


  • Impact of pre‐ablation weight loss on the success of catheter ablation for atrial fibrillation

    by Graham Peigh, Jeremiah Wasserlauf, Kelly Vogel, Rachel M. Kaplan, Anna Pfenniger, Daniel Marks, Arjun Mehta, Alexandru B. Chicos, Rishi Arora, Susan Kim, et al.

    Introduction: Obesity is an established risk factor for recurrent atrial fibrillation (AF) after ablation. The impact of pre‐procedure weight changes on freedom from AF (FFAF) after ablation in obese and nonobese patients is unknown.Methods: A single‐center retrospective cohort study of patients undergoing pulmonary vein isolation was performed. Before ablation, all candidates were encouraged to adopt healthy lifestyle habits according to American Heart Association guidelines, including weight loss, by their physician. The primary endpoint was FFAF through 1‐year after completion of the 3‐month blanking period.Results: Of the 601 patients (68% male; average age 62.1 ± 10.3 years) included in analysis, 234 patients (38.9%) were obese (body mass index ≥ 30) and 315 (52.4%) had paroxysmal AF. FFAF was observed in 420 patients (69.9%) at 15 months. Percent change in weight that occurred during the year before ablation independently predicted FFAF through 15‐months in all patients (adjusted odds ratio = 1.17, 95% confidence interval: 1.11–1.23). Subgroup analyses based on paroxysmal vs persistent AF, presence of obesity, and history of prior ablation were performed. Percent change in weight over the year before ablation was independently associated with FFAF in all subgroups except nonobese patients with persistent AF.Conclusion: Pre‐ablation weight loss was associated with FFAF in both obese and nonobese patients. Further studies are needed to define the optimal approach to weight loss before AF ablation.